Lutetium-177 (177Lu) EVG321 - Evergreen Theragnostics
Alternative Names: EVG-321Latest Information Update: 08 Jun 2024
At a glance
- Originator Innsbruck Medical University
- Developer Evergreen Theragnostics; Innsbruck Medical University
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 28 May 2024 Preclinical trials in Small cell lung cancer in USA (Parenteral) prior to May 2024
- 21 May 2024 Evergreen Theragnostics enters into collaboration and licensing agreement for the clinical development of EVG 321 for small cell lung cancer
- 21 May 2024 Evergreen Theragnotics plans registration enabling therapeutic clinical trials for Lutetium-177 (177Lu) EVG321